About Veracyte (NASDAQ:VCYT)
Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. It sells its products through its product specialists, institutional managers, account managers, and medical science specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300
Debt
Debt-to-Equity Ratio0.68%
Current Ratio4.49%
Quick Ratio4.04%
Price-To-Earnings
Trailing P/E Ratio-6.34
Forward P/E Ratio-6.71
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.95 million
Price / Sales2.75
Cash FlowN/A
Price / CashN/A
Book Value$1.09 per share
Price / Book5.29
Profitability
EPS (Most Recent Fiscal Year)($0.91)
Net Income$-31,000,000.00
Net Margins-43.09%
Return on Equity-68.43%
Return on Assets-36.13%
Miscellaneous
Employees246
Outstanding Shares34,290,000
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte (NASDAQ:VCYT) released its earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.03. The biotechnology company earned $19.60 million during the quarter, compared to the consensus estimate of $18.84 million. Veracyte had a negative return on equity of 68.43% and a negative net margin of 43.09%. View Veracyte's Earnings History.
When is Veracyte's next earnings date?
What price target have analysts set for VCYT?
5 brokers have issued 12 month target prices for Veracyte's stock. Their predictions range from $5.40 to $15.00. On average, they expect Veracyte's stock price to reach $11.08 in the next year. View Analyst Ratings for Veracyte.
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include Albireo Pharma (ALBO), Oxford BioMedica (OXB), Mersana Therapeutics (MRSN), Utah Medical Products (UTMD), Cambian Group (CMBN), Durect (DRRX), Strongbridge Biopharma (SBBP), Idera Pharmaceuticals (IDRA), Corbus Pharmaceuticals (CRBP), Antares Pharma (ATRS), GTX (GTXI), Quanterix (QTRX), Solid Biosciences (SLDB), Clearside Biomedical (CLSD), Cellular Biomedicine (CBMG), Dermira (DERM), Pieris Pharmaceuticals (PIRS) and SafeStitch Medical (TRXC).
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 60)
- Mr. Christopher M. Hall, Pres & COO (Age 49)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Principal Accounting Officer (Age 48)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific Officer & Head of Scientific, Clinical and Medical Affairs Department (Age 59)
- Mr. Ashish Kheterpal, Chief Information Officer
Has Veracyte been receiving favorable news coverage?
Media coverage about VCYT stock has been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Veracyte earned a media sentiment score of 0.09 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $5.77.
How big of a company is Veracyte?
Veracyte has a market capitalization of $196.49 million and generates $71.95 million in revenue each year. The biotechnology company earns $-31,000,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Veracyte employs 246 workers across the globe.
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Veracyte (NASDAQ:VCYT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Veracyte in the last 12 months. Their average twelve-month price target is $11.08, suggesting that the stock has a possible upside of 92.03%. The high price target for VCYT is $15.00 and the low price target for VCYT is $5.40. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.60 | 2.60 | 2.60 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $11.08 | $11.08 | $12.50 | $13.25 |
| Price Target Upside: | 92.03% upside | 86.85% upside | 95.31% upside | 61.59% upside |
Veracyte (NASDAQ:VCYT) Consensus Price Target History
Veracyte (NASDAQ:VCYT) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Veracyte (NASDAQ:VCYT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Veracyte (NASDAQ VCYT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 70.45%
Veracyte (NASDAQ VCYT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/20/2017 | Bonnie H Anderson | Chairman | Sell | 16,000 | $9.41 | $150,560.00 | 16,000 |  |
| 10/18/2017 | Bonnie H Anderson | CEO | Sell | 6,000 | $9.09 | $54,540.00 | 16,000 | |
| 10/2/2017 | Christopher M Hall | Insider | Sell | 20,000 | $9.00 | $180,000.00 | | |
| 9/25/2017 | Bonnie H Anderson | Chairman | Sell | 6,000 | $8.44 | $50,640.00 | 16,000 | |
| 8/28/2017 | Evan/ Fa Jones | Director | Sell | 22,500 | $7.81 | $175,725.00 | | |
| 8/24/2017 | Evan/ Fa Jones | Director | Sell | 40,000 | $7.88 | $315,200.00 | | |
| 8/23/2017 | Evan/ Fa Jones | Director | Sell | 20,000 | $7.92 | $158,400.00 | | |
| 5/16/2017 | Jesse I Treu | Director | Sell | 2,226 | $8.08 | $17,986.08 | 1,642 | |
| 3/21/2017 | Bonnie H Anderson | Chairman | Sell | 5,000 | $9.09 | $45,450.00 | 15,000 | |
| 6/3/2016 | Bonnie H Anderson | CEO | Buy | 5,000 | $5.40 | $27,000.00 | 7,500 | |
| 6/1/2016 | Bonnie H Anderson | CEO | Buy | 5,000 | $5.46 | $27,300.00 | 2,500 | |
| 5/31/2016 | Bonnie H Anderson | CEO | Buy | 2,500 | $5.46 | $13,650.00 | 2,500 | |
| 11/25/2015 | Evan/ Fa Jones | Director | Sell | 7,896 | $7.23 | $57,088.08 | | |
| 11/24/2015 | Evan/ Fa Jones | Director | Sell | 7,104 | $7.20 | $51,148.80 | | |
| 7/22/2015 | Christopher M Hall | COO | Sell | 2,500 | $11.85 | $29,625.00 | | |
| 6/26/2015 | Shelly D Guyer | CFO | Sell | 1,000 | $12.08 | $12,080.00 | | |
| 9/10/2014 | Christopher M Hall | Insider | Sell | 1,000 | $12.29 | $12,290.00 | | |
| 9/9/2014 | Evan/ Fa Jones | Director | Sell | 27,304 | $12.60 | $344,030.40 | | |
| 8/18/2014 | Christopher M Hall | Insider | Sell | 1,000 | $12.92 | $12,920.00 | | |
| 7/29/2014 | Julie Brooks | EVP | Buy | 1,122 | $14.69 | $16,482.18 | | |
| 7/28/2014 | Julie Brooks | EVP | Buy | 1,000 | $14.71 | $14,710.00 | | |
| 7/22/2014 | Julie Brooks | VP | Buy | 2,000 | $14.18 | $28,360.00 | | |
| 7/21/2014 | Julie Brooks | VP | Buy | 1,000 | $14.00 | $14,000.00 | | |
| 7/10/2014 | Christopher M Hall | Insider | Sell | 3,000 | $14.92 | $44,760.00 | | |
| 6/27/2014 | Bonnie H Anderson | CEO | Sell | 1,000 | $17.95 | $17,950.00 | | |
| 6/23/2014 | Bonnie H Anderson | CEO | Sell | 4,000 | $16.45 | $65,800.00 | | |
| 6/23/2014 | Christopher M Hall | Insider | Sell | 2,000 | $16.95 | $33,900.00 | | |
| 6/20/2014 | Shelly D Guyer | CFO | Sell | 1,250 | $16.04 | $20,050.00 | | |
| 6/19/2014 | Christopher M Hall | Insider | Sell | 3,000 | $14.99 | $44,970.00 | | |
| 6/12/2014 | Evan/ Fa Jones | Director | Sell | 16,650 | $15.07 | $250,915.50 | | |
| 6/9/2014 | Evan/ Fa Jones | Director | Sell | 22,870 | $14.57 | $333,215.90 | | |
| 6/5/2014 | Evan/ Fa Jones | Director | Sell | 28,248 | $14.33 | $404,793.84 | | |
| 5/30/2014 | Evan/ Fa Jones | Director | Sell | 23,882 | $15.33 | $366,111.06 | | |
(Data available from 1/1/2013 forward)
Veracyte (NASDAQ VCYT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Veracyte (VCYT) vs. Its Rivals Critical Analysis
www.americanbankingnews.com - April 18 at 11:14 AM |
| Contrasting Veracyte (VCYT) & Its Competitors
www.americanbankingnews.com - April 17 at 5:20 PM |
 | Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on Tuesday, May 1, 2018
finance.yahoo.com - April 17 at 4:53 PM |
| Veracyte (VCYT) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - April 17 at 12:21 PM |
| Comparing Veracyte (VCYT) and The Competition
www.americanbankingnews.com - April 15 at 9:09 PM |
| Head to Head Comparison: Veracyte (VCYT) vs. Its Rivals
www.americanbankingnews.com - April 13 at 9:31 AM |
| Veracyte (VCYT) Given a $13.00 Price Target at BTIG Research
www.americanbankingnews.com - April 12 at 10:19 AM |
| Veracyte (VCYT) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 12 at 9:51 AM |
| Critical Review: Veracyte (VCYT) & Its Rivals
www.americanbankingnews.com - April 12 at 9:11 AM |
| Head to Head Comparison: Veracyte (VCYT) & Its Competitors
www.americanbankingnews.com - April 12 at 1:15 AM |
| Veracyte (VCYT) & Its Peers Head-To-Head Analysis
www.americanbankingnews.com - April 9 at 7:21 PM |
| Head-To-Head Analysis: Veracyte (VCYT) versus Its Peers
www.americanbankingnews.com - April 8 at 7:20 AM |
| Zacks: Analysts Anticipate Veracyte (VCYT) Will Announce Quarterly Sales of $18.32 Million
www.americanbankingnews.com - April 5 at 2:12 AM |
| Biocept (BIOC) vs. Veracyte (VCYT) Head to Head Contrast
www.americanbankingnews.com - April 4 at 9:20 PM |
| Veracyte (VCYT) versus The Competition Financial Comparison
www.americanbankingnews.com - April 4 at 3:06 AM |
| Zacks: Brokerages Anticipate Veracyte (VCYT) to Post -$0.25 EPS
www.americanbankingnews.com - April 3 at 9:19 PM |
| Veracyte (VCYT) Downgraded to Neutral at Piper Jaffray
www.americanbankingnews.com - April 1 at 4:48 PM |
| Veracyte Inc (VCYT) to Post Q1 2019 Earnings of ($0.21) Per Share, William Blair Forecasts
www.americanbankingnews.com - March 23 at 12:34 PM |
| Veracyte Unveils Afirma Xpression Atlas Platform at ENDO 2018
finance.yahoo.com - March 19 at 4:22 PM |
| Veracyte Announces New Data Suggesting Afirma GSC’s Ability to Help Significantly More Patients Avoid Unnecessary Thyroid Surgery
finance.yahoo.com - March 19 at 9:39 AM |
| Veracyte Inc (VCYT) Expected to Announce Quarterly Sales of $18.31 Million
www.americanbankingnews.com - March 19 at 2:28 AM |
| Veracyte Inc (VCYT) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 18 at 9:42 AM |
 | Veracyte (VCYT) Says New Data Demonstrating Real-World Performance of Afirma GSC to Be Presented at ENDO
www.streetinsider.com - March 15 at 9:22 AM |
| Q1 2018 EPS Estimates for Veracyte Inc Lowered by Analyst (VCYT)
www.americanbankingnews.com - March 15 at 6:26 AM |
| Veracyte (VCYT) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 6 at 3:32 PM |
| Stonepine Capital Management LLC Increases Position in Veracyte Inc (VCYT)
www.americanbankingnews.com - March 6 at 2:57 PM |
| Leerink Swann Comments on Veracyte Inc's Q1 2018 Earnings (VCYT)
www.americanbankingnews.com - March 5 at 1:10 AM |
| Veracyte Inc (VCYT) Shares Sold by Broadfin Capital LLC
www.americanbankingnews.com - March 3 at 4:53 AM |
| Zacks: Analysts Anticipate Veracyte Inc (VCYT) Will Announce Quarterly Sales of $19.08 Million
www.americanbankingnews.com - March 2 at 3:02 AM |
| Piper Jaffray Companies Reiterates Hold Rating for Veracyte (VCYT)
www.americanbankingnews.com - March 1 at 8:13 PM |
| Veracyte Q4 Earnings Preview
finance.yahoo.com - February 27 at 5:03 PM |
| Veracyte Inc to Host Earnings Call
finance.yahoo.com - February 27 at 5:03 PM |
| Veracyte Announces Fourth Quarter and Full-Year 2017 Financial Results, Provides 2018 Financial Outlook
finance.yahoo.com - February 27 at 5:03 PM |
| Veracyte Inc (VCYT) Shares Bought by ARK Investment Management LLC
www.americanbankingnews.com - February 26 at 5:08 AM |
| Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018
finance.yahoo.com - February 12 at 9:06 AM |
| Veracyte (VCYT) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - February 4 at 9:02 AM |
| Veracyte to Present at LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - January 31 at 9:23 AM |
| Brokers Set Expectations for Veracyte Inc's Q1 2019 Earnings (VCYT)
www.americanbankingnews.com - January 29 at 7:30 AM |
| Veracyte Inc (VCYT) Expected to Post Quarterly Sales of $18.84 Million
www.americanbankingnews.com - January 28 at 6:26 AM |
| Veracyte Inc (VCYT) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 27 at 10:32 AM |
| Veracyte Announces 100,000th Afirma Test Performed to Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
finance.yahoo.com - January 25 at 4:25 PM |
| Veracyte’s Chief Science and Medical Officer to Present at The Precision Medicine World Conference
finance.yahoo.com - January 19 at 4:52 PM |
| Veracyte Announces Publication of Results from Patient Survey Quantifying the Challenges in Diagnosing Interstitial Lung Disease
finance.yahoo.com - January 18 at 11:35 AM |
| -$0.20 Earnings Per Share Expected for Veracyte, Inc. (VCYT) This Quarter
www.americanbankingnews.com - January 8 at 11:06 PM |
| Veracyte Announces Strategic Realignment and New Appointments to Advance Commercial Growth
finance.yahoo.com - January 8 at 10:40 AM |
| Veracyte, Inc. (VCYT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 2 at 9:58 AM |
| $18.84 Million in Sales Expected for Veracyte, Inc. (VCYT) This Quarter
www.americanbankingnews.com - December 25 at 10:32 AM |
| Veracyte, Inc. (VCYT) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - December 23 at 3:30 PM |
| InVitae (NVTA) and Veracyte (VCYT) Financial Contrast
www.americanbankingnews.com - December 15 at 9:46 AM |
| Are Options Traders Betting on a Big Move in Veracyte (VCYT) Stock?
finance.yahoo.com - December 14 at 10:37 AM |
Veracyte (NASDAQ:VCYT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Veracyte (NASDAQ:VCYT) Income Statement, Balance Sheet and Cash Flow Statement
Veracyte (NASDAQ VCYT) Stock Chart for Friday, April, 20, 2018
Loading chart…
